Rein Therapeutics Inc.

NasdaqCM:RNTX Stock Report

Market Cap: US$88.3m

Rein Therapeutics Management

Management criteria checks 3/4

Rein Therapeutics' CEO is James Windsor, appointed in Oct 2023, has a tenure of 2.67 years. total yearly compensation is $882.70K, comprised of 65.1% salary and 34.9% bonuses, including company stock and options. directly owns 0.029% of the company’s shares, worth $25.66K. The average tenure of the management team and the board of directors is 2.5 years and 7.6 years respectively.

Key information

James Windsor

Chief executive officer

US$882.7k

Total compensation

CEO salary percentage65.14%
CEO tenure2.7yrs
CEO ownership0.03%
Management average tenure2.5yrs
Board average tenure7.6yrs

Recent management updates

Recent updates

Analysis Article • Aug 18

Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 30

Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Oct 21

Aileron Therapeutics: An Assessment On A Lottery Ticket

Today, we take an in-depth look at a small biotech concern that is very deep in 'Busted IPO' territory. The company is focused on developing a treatment to reduce the negative symptoms of chemotherapy. A full investment analysis is presented in the paragraphs.

CEO Compensation Analysis

How has James Windsor's remuneration changed compared to Rein Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$50m

Dec 31 2025US$883kUS$575k

-US$50m

Sep 30 2025n/an/a

-US$59m

Jun 30 2025n/an/a

-US$59m

Mar 31 2025n/an/a

-US$61m

Dec 31 2024US$2mUS$506k

-US$63m

Sep 30 2024n/an/a

-US$29m

Jun 30 2024n/an/a

-US$25m

Mar 31 2024n/an/a

-US$18m

Dec 31 2023US$716kUS$85k

-US$16m

Compensation vs Market: James's total compensation ($USD882.70K) is above average for companies of similar size in the US market ($USD642.98K).

Compensation vs Earnings: James's compensation has been consistent with company performance over the past year.

CEO

James Windsor (59 yo)

2.7yrs
Tenure
US$882,695
Compensation

Dr. James Brian Windsor, Ph.D. is Chief Executive Officer and Director of Rein Therapeutics Inc. (formerly known as Aileron Therapeutics, Inc.) from March 11, 2024 and its President since October 2023. Dr....

Leadership Team

NamePositionTenureCompensationOwnership
James Windsor
CEO, President & Director2.7yrsUS$882.70k0.029%
$ 25.7k
Timothy Cunningham
Interim CFO & Principal Accounting Officer2.1yrsUS$433.94kno data
Cory Hogaboam
Chief Scientific Officerno datano datano data
Jennifer Faigle
Counselno datano datano data
Ron Chen
VP of Finance and Corporate Controller2.5yrsno datano data
2.5yrs
Average Tenure

Experienced Management: RNTX's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
James Windsor
CEO, President & Director2.3yrsUS$882.70k0.029%
$ 25.7k
Josef H. Rickenbach
Independent Chairman7yrsUS$134.55k0.067%
$ 59.3k
Alan Musso
Independent Director2.7yrsUS$94.55k0.063%
$ 55.2k
Carol Prives
Member of Scientific Advisory Board8.3yrsno datano data
Brian Druker
Member of Scientific Advisory Board8.3yrsno datano data
Alan List
Member of Scientific Advisory Board8.3yrsno datano data
Reinhard Ambros
Independent Lead Director13yrsUS$92.05k0.057%
$ 49.9k
William Fairey
Independent Director2.7yrsUS$83.30k0.063%
$ 55.2k
Ulrich Steidl
Member of Scientific Advisory Boardno datano datano data
7.6yrs
Average Tenure
70yo
Average Age

Experienced Board: RNTX's board of directors are considered experienced (7.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/09 13:47
End of Day Share Price 2026/06/09 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rein Therapeutics Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ying HuangBofA Global Research
Brian Kemp DolliverBrookline Capital Markets
John NewmanCanaccord Genuity